The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Spectranetics beat slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP earnings per share dropped to a loss.
Gross margins increased, operating margins improved, and net margins dropped.
Spectranetics notched revenue of $32.5 million. The five analysts polled by S&P Capital IQ looked for sales of $31.9 million on the same basis. GAAP reported sales were 11% higher than the prior-year quarter's $29.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.04. The six earnings estimates compiled by S&P Capital IQ predicted $0.02 per share on the same basis. GAAP EPS were -$0.06 for Q4 versus $0.02 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 72.9%, 240 basis points better than the prior-year quarter. Operating margin was 5.7%, 80 basis points better than the prior-year quarter. Net margin was -6.2%, 800 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $32.5 million. On the bottom line, the average EPS estimate is $0.01.
Next year's average estimate for revenue is $135.6 million. The average EPS estimate is $0.09.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 158 members out of 170 rating the stock outperform, and 12 members rating it underperform. Among 38 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 35 give Spectranetics a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Spectranetics is buy, with an average price target of $10.46.
The health-care investing landscape is littered with also-rans and a few major winners. Is Spectranetics performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add Spectranetics to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.